ABOUT CYTEL

Now more than ever, the clinical development path is full of make-or-break data complexities and analytical challenges. As a pioneer in evidence generation, with deep expertise in advanced analytical solutions, we are uniquely equipped to unlock the value from increasingly complex data. Life Sciences companies count on Cytel to deliver exceptional insight, minimize trial risk and accelerate the development of promising new medicines that improve human life. Cytel provides software solutions for the design and analysis of clinical trials, including industry standards East®, StatXact® and LogXact®, as well as data-focused clinical research services. With operations across North America, Europe, and India, Cytel employs 900 professionals, with strong talent in biostatistics, programming, and data management. For more information about Cytel, visit http://www.cytel.com/.

FEATURED PRODUCTS

Adaptive Trial Design and Implementation Adaptive Trial Design and Implementation

Cytel brings its expertise in adaptive designs to the design and implementation of the industry’s most innovative clinical trials. These highly flexible trials raise peculiar challenges for enrollment, data collection and regulatory submission. Why not have the industry leaders in adaptive design working on your adaptive trials?

Data-Focused Clinical Research Services Data-Focused Clinical Research Services

Cytel’s dedicated team of professionals is here to help you address an array of challenges when conducting drug development. Whether you face a complex statistical issue or the need for knowledgeable collaborators to handle biometrics and trial implementation, Cytel has skilled professionals available when you need them.

Data Science Data Science

Cytel data scientists apply advanced statistical techniques including predictive modeling of biological processes and drug interactions to unlock the potential of big data. Our team supports biomarker discovery and diagnostic test development based on biomedical signals and images, and real world evidence analysis.

Quantitative Pharmacology and Pharmacometrics Quantitative Pharmacology and Pharmacometrics

Exposure (and Dose) Response Analyses, including pharmacokinetic and pharmacodynamics analyses, guide critical decisions in drug development. Cytel’s expert Quantitative Pharmacology and Pharmacometrics group delivers high quality solutions to help our customers get those decisions right.

CDISC Services CDISC Services

Cytel has a strong track record in providing CDISC solutions and we are a CDISC Registered Solutions Provider. We have converted more than 150 studies as part of NDA submissions, all of which have been accepted by the FDA. The Clinical Data Interchange Standards Consortium (CDISC) devised the SDTM and ADaM models to standardize data structures for submission of raw and analysis data from clinical trials. These standard formats are increasingly expected by regulatory authorities including the FDA.

East Trial Design Software East Trial Design Software

Extensive time and energy is often spent designing feasible clinical studies. East's broad range of statistical tools and expert simulations provides an invaluable resource for the rapid construction of trial designs. Illuminating graphs and charts allow for accessible comparison, while a user-friendly interface encourages exploration and experiment.

EnForeSys Enrollment Forecasting Software EnForeSys Enrollment Forecasting Software

EnForeSys is a user-friendly decision tool that leverages simulation methods to predict recruitment milestones with high accuracy. Armed with a reliable probability of success, you can rest assured that your trial will reach its targeted enrollment on time and on budget.

Strategic Consulting Strategic Consulting

We believe that expert statistical input has the power to shape the future of clinical development: de-risking portfolios, accelerating timelines, and increasing the probability of success.

CONTACT INFORMATION

Cytel

675 Massachusetts Ave # 3

Cambridge, MA 02139

UNITED STATES

Phone: 617-661-2011

Contact: Liz Cole

FEATURED ARTICLES

  • 2018 vs. 2010 FDA Draft Guidance For Industry On Adaptive Designs For Clinical Trials Of Drugs and Biologics
    2018 vs. 2010 FDA Draft Guidance For Industry On Adaptive Designs For Clinical Trials Of Drugs and Biologics

    In September 2018, FDA issued a new draft Guidance for Industry on Adaptive Designs for Clinical Trials of Drugs and Biologics. This guidance replaces the previously published 2010 draft guidance. Here, we summarize the differences between the two documents and highlight any significant new elements introduced in the most recent material. Of note, the 2018 guidance is more compact and streamlined than its 2010 predecessor, also evident by a fewer number of total pages (36 vs. 50 in the 2010 version).

  • Cytel And Axio Join Forces To Create An Industry Leader In Analytical Solutions For Drug Development

    Cytel Inc., the leading global provider of innovative analytical software and services to the life sciences industry, and Axio Research, a premier provider of biostatistics to pharmaceutical, biotechnology and medical device companies, today announced that they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for the life sciences industry.

  • Opening The Black Box: Moving To Explainable AI
    Opening The Black Box: Moving To Explainable AI

    For the biopharma industries specifically, AI represents an opportunity to avert the R&D productivity crisis with paradigm-shifting applications such as in-silico drug design, prediction of trial risks and big data analytics. However, with every opportunity, there are risks and challenges, and this blog discusses how pharma needs to address the opacity of AI to ensure trust and credibility with all stakeholders.

  • Assuring Outsourcing Obligations With Specialist Data Management Oversight
    Assuring Outsourcing Obligations With Specialist Data Management Oversight

    This blog discusses how specialist CROs can add value and streamline processes by providing oversight of data management services delivered by another CRO. This model helps to fulfill essential regulatory obligations for biopharma companies who may lack their own internal oversight resources.

  • Applying Biomarker Driven Strategies In Drug Development
    Applying Biomarker Driven Strategies In Drug Development

    Determining appropriate stratifications and relevant clinical endpoints for specific sub-populations can be challenging. Therefore, it is necessary for development strategies to incorporate explorations and determinations of suitable biomarkers early in the development of a new therapy.

  • Ensuring Robust ePRO Implementation: Factors For Success
    Ensuring Robust ePRO Implementation: Factors For Success

    In this blog, Jonathan Pritchard, Director Business Development at Cytel, draws on his experience in commercial, clinical and technology roles within the biopharmaceutical industry and shares his insights on the primary considerations for sponsors when implementing an ePRO solution.

  • Could Adaptive Designs Be The Answer To Oncology Clinical Development Success?
    Could Adaptive Designs Be The Answer To Oncology Clinical Development Success?

    Across all therapeutic areas, clinical development faces well-documented, critical challenges that impact the pharmaceutical industry's ability to bring new medicines to patients – but in the oncology space, these issues are particularly acute. Read how adaptive trial designs can help address the challenges encountered in anti-cancer clinical development today by saving time, resources and improving the odds of success.

  • The Model-Based Approach: A Better Way To Forecast Enrollment
    The Model-Based Approach: A Better Way To Forecast Enrollment

    Compared to conventional approaches, a model-based approach to enrollment forecasting provides a more realistic assessment of the possible risks and outcomes for any given scenario, by accounting for the nonlinearity and randomness of real-life enrollment processes. In addition, a model-based approach offers many more advantages other than more realistic expectations.

  • Creating A Common Language: Forging Statistical And Clinical Collaborations
    Creating A Common Language: Forging Statistical And Clinical Collaborations

    This article will provide helpful pointers from  Paul Terrill, Director of Strategic Consulting at Cytel to ensure smooth communication between statistical and clinical stakeholders.

  • Data Management Fundamentals For Your Next Clinical Trial
    Data Management Fundamentals For Your Next Clinical Trial

    Data is the most crucial asset in any clinical trial and is used to ultimately drive the decision-making process related to the development candidate. Therefore, for any sponsor, paying close attention to the data management aspects of clinical operations should be paramount. The principles of data management are simple and well-founded. However, the application of these principles needs careful consideration, depending on various scenarios and the size of the organization. When implementing data management for your trial, it is critical to plan ahead and fully understand all the steps and activities involved.

  • What Makes A Good Data Manager? Infographic
    What Makes A Good Data Manager? Infographic

    Data managers need to equip themselves with skills to make sense of an ever-expanding world, while maintaining adherence to core principles of safety and efficacy.

  • What Makes A Good Data Manager?
    What Makes A Good Data Manager?

    In this blog, Paul Fardy, Executive Director of Data Management at Cytel shares his thoughts on how the data manager role has evolved.

  • In The Midst Of This: The Data Management Perspective On The Interim Analysis
    In The Midst Of This: The Data Management Perspective On The Interim Analysis

    Patti Arsenault, Cytel's Global Head of Data Management, shares her thoughts on the three core elements important for the success from the data management standpoint - effective timeline management, thoughtful database design, and a proactive approach to data cleaning.

  • Decisions For Your Next Trial: When To Adopt The CDISC Data Standard
    Decisions For Your Next Trial: When To Adopt The CDISC Data Standard

    Trial sponsors must carefully plan their data consolidation and analysis strategies not only in preparation for CDISC-compliant submissions, but to respond to market influences and evolving clinical partnership models.

  • Data Science: Bridging The Gap Between Controlled Experiment And Real-World Data?
    Data Science: Bridging The Gap Between Controlled Experiment And Real-World Data?

    Results from a recent Deloitte survey explored if data science could be about to revolutionize the regulatory approval of new drugs.

  • Critical Operational Considerations For Interim Analyses
    Critical Operational Considerations For Interim Analyses

    Highlights from Adam Hamm, Director Biostatistics at Cytel, presentation on best practices and operational considerations for adaptive designs and interim analyses.

  • Addressing The Problem Of Feature Selection Using Genetic Algorithms
    Addressing The Problem Of Feature Selection Using Genetic Algorithms

    In the new era of big and complex data, conventional methods of solving search problems are sometimes ineffective.Genetic algorithms provide a highly effective solution to many such problems, and therefore their popularity and adoption are on the rise.

  • 5 Reasons To Integrate Model-Based Meta-Analyses (MBMA) Into Your Clinical Development Strategy
    5 Reasons To Integrate Model-Based Meta-Analyses (MBMA) Into Your Clinical Development Strategy

    An important trend in clinical development involves integrating strategic pharmacometric analysis with program-level decision making to make the most use of available data. This article highlights five reasons why you should consider utilizing model-based meta-analyses (MBMAs) for your program or portfolio development.

  • Non-Compartmental Analysis And The Early Phase Regulatory Environment
    Non-Compartmental Analysis And The Early Phase Regulatory Environment

    NCAs are an integral part of establishing an early phase audit trail, it is important to use NCA software that streamlines a detailed and complex workflow.

  • Novel immunotherapies Lean On Old Methods For Statistical Challenges
    Novel immunotherapies Lean On Old Methods For Statistical Challenges

    Many drugs in the IO arena do not follow well understood traditions so the standard statistical approaches to evaluating safety and efficacy may not always be optimal or efficient. As it turns out, as is often the case with methodological research, that alternative methods are available, have been for a long time.